Archana Bommi‐Reddy

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index1.7kcitations39works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(29), Multiple Myeloma Research and Treatments(22), Click Chemistry and Applications(7), Histone Deacetylase Inhibitors Research(7), Epigenetics and DNA Methylation(5)

Publications39 total

Cell line information from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supporting data Fig 4A from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supporting data Fig 3A, 3B, 4D, S6 from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figure legends from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary tables from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Data from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figures from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figures from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary Materials and Methods from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supporting data Fig 4A from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Data from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary Materials and Methods from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary tables from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Cell line information from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supplementary figure legends from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Supporting data Fig 3A, 3B, 4D, S6 from Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response
2023Open Access
Updated Findings and Biomarker Analysis From the Ongoing Phase 1 Study of Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors
European Journal of Cancer·2022· 1 cited
CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells
PLoS ONE·2022· 16 citedOpen Access
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma
Neuro-Oncology·2022· 24 citedOpen Access
CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells
2021· 2 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Robert J. Sims(31), Andrew R. Conery(28), Barbara M. Bryant(26), Richard C. Centore(22), Jennifer A. Mertz(22), Kerry L. Spillane(21), Charlie Hatton(19), Nicole E. Follmer(18), Patricia Greninger(18), Arnaud Amzallag(18), Cyril H. Benes(18), Jonathan E. Wilson(8), Patricia J. Keller(6), Michael J. Steinbaugh(6), Annissa J. Huhn(5), Florence Poy(5), Richard Cummings(5), Shivangi Joshi(4), Péter Sandy(4), Eneida Pardo(4)